哺乳动物雷帕霉素靶蛋白复合物2靶向治疗肿瘤的研究进展

Targeted Inhibition of mTORC2 in Treating Cancer

小分子抑制剂选择性的靶向杀伤肿瘤细胞,而对正常细胞无毒副作用,显示出很好的抗肿瘤前景。哺乳动物雷帕霉素靶蛋白复合物2(mTORC2)是一个非常有希望的靶点,最近研究发现mTORC2的活性在多种肿瘤的形成和侵袭中是必不可少的,而且mTORC2抑制剂靶向治疗肿瘤有着广泛的影响。本文就mTORC2的生物学特性及以mTORC2为靶点治疗肿瘤的前景进行综述。

Small molecular inhibitors that selectively target cancer cells instead of normal cells are promising anti-cancer therapeutics. The mammalian target of rapamycin complex 2 （ mTORC2 ） is emerging as a potential target for inhibitors. Recent studies in oncobiology have indicated that the mTORC2 activity is essential for the transformation, as well as the vitality, of a number of cancer cell types, and that the mTORC2 inhibitor has a broad impact on cancer therapy. In the present study, new findings on the biology of mTORC2 signaling are summarized, and future prospects for roTOR-targeted therapy are highlighted.